Nocturnal melatonin levels are unaltered by ovarian suppression in girls with central precocious puberty

Berga, Sarah L.; Jones, Kenneth L.; Kaufmann, Silvia; Yen, S. S. C.

doi:10.1016/s0015-0282(16)53155-0

Cited by 27 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It seems that the antigonadal action of melatonin is not related to circulating gonadotrophins or sex steroid levels. Similar observations were also demonstrated by other investigators (Berga et al ., 1989; Wilson et al ., 1993; Delfs et al ., 1994). Moreover, supporting our findings, Walker et al .…”

supporting

confidence: 93%

“…(1996c) in their previous report suggested that gonadotrophins, GnRH and/or oestradiol may modulate plasma melatonin levels. Moreover, contrary to the authors' suggestion, low melatonin levels in patients with central precocious puberty (CPP) either did not change or declined further after GnRH agonist treatment in spite of causing pituitary gonadal suppression (Berga et al ., 1989; Waldhauser et al ., 1991). Thus, we consider that, contrary to the authors' suggestion, regulation of melatonin in Klinefelter's syndrome and CPP is not similar.…”

mentioning

confidence: 80%

See 1 more Smart Citation

Effects of testosterone treatment on plasma melatonin levels in male hypogonadism

Özata

Beyhan

1998

Clinical Endocrinology

View full text Add to dashboard Cite

supporting

confidence: 93%

mentioning

confidence: 80%

Effects of testosterone treatment on plasma melatonin levels in male hypogonadism

Özata

Beyhan

1998

Clinical Endocrinology

View full text Add to dashboard Cite

“…Nocturnal melatonin concentrations were similar in ovariectomized females and females treated with oestradiol from immaturity through the initiation of LH secretion, characterizing the onset of puberty. These longitudinal data support short-term observa¬ tions in girls that nocturnal melatonin concentrations are unchanged following both gonadal suppression during precocious puberty (Berga et al 1989) and ethinyloestradiol therapy for Turner's syndrome (Schober et al 1989), suggesting that some nongonadal developmental mechanism regulates the amplitude of the photoperiodic-induced 24-h rhythm to melatonin secretion.…”

Section: Discussionsupporting

confidence: 72%

“…Oestradiol treatment of ovariectomized ewes lowers nocturnal melatonin secretion ) and the administration of ethinyloestradiol to induce secondary sexual characteristics in a girl resulted in a decrease in the urinary excretion of a melatonin metabolite (Arendt et al 1989). in con¬ trast, nocturnal melatonin levels in girls are unchanged following gonadal suppression during pre¬ cocious puberty (Berga et al 1989) and ethinyloestra¬ diol therapy for Turner's syndrome (Schober et al 1989). The effects of oestradiol on the developmental change in the 24 -h melatonin rhythm have not been assessed.…”

Section: Introductionmentioning

confidence: 99%

The amplitude of nocturnal melatonin concentrations is not decreased by oestradiol and does not alter reproductive function in adolescent or adult female rhesus monkeys

Wilson

Lackey²,

Chikazawa³

et al. 1993

Journal of Endocrinology

View full text Add to dashboard Cite

Nocturnal concentrations of melatonin in serum decline significantly with advancing pubertal development in both children and non-human primates and elevated levels may be associated with anovulation in adults. Three studies, using female rhesus monkeys, were performed to determine whether (1) the decline in nocturnal melatonin concentrations in adolescents was due to maturational increases in serum oestradiol, (2) the experimental elevation in nocturnal melatonin would delay the normal progression of puberty in post-menarchial monkeys, and (3) the experimental elevation in nocturnal melatonin would disrupt normal ovulatory function in adults. In experiment 1, juvenile female rhesus monkeys, housed indoors in a fixed photoperiod (12 h light:12 h darkness), were assigned randomly to one of two treatment groups: ovariectomized with no replacement therapy (control; n = 4) or ovariectomized with oestradiol replacement therapy maintaining oestradiol at approximately 90 pmol/l (treated; n = 8). Twenty-four hour as well as daytime serum samples were collected from 19 to 35 months of age. Nocturnal melatonin concentrations declined significantly in all females with advancing chronological age and this change was unaffected by oestradiol treatment. The decline in nocturnal melatonin concentrations occurred, on average, 2.0 +/- 0.2 months after the initial rise in serum LH in control females and 6.0 +/- 0.8 months in treated females. Furthermore, this decline in night-time melatonin was not related to significant developmental changes in body weight. In experiment 2, control (n = 6) and melatonin-treated (treated; n = 6) adolescent female monkeys were studied from -30 to +105 days from menarche. Beginning at 45 days following menarche, treated females received 30 days of nocturnal melatonin infusion to elevate levels to prepubertal values. Developmental changes in perineal swelling and coloration as well as serum oestradiol and insulin-like growth factor-I (IGF-I) were compared with values observed during the 45-day pretreatment and 30-day post-treatment conditions as well as with those observed in control females. Despite a significant elevation in nightly melatonin levels for the 30-day period in treated females, developmental changes in oestradiol, IGF-I, and perineal coloration and swelling were not different compared with the control females. In experiment 3, adult females were given melatonin nightly beginning on the first day of menses following an ovulatory cycle and treatment was continued for 45 days or until the next menstruation occurred. Melatonin was elevated to supraphysiological levels every night throughout the treatment period.(ABSTRACT TRUNCATED AT 400 WORDS)

show abstract

“…Although we did not measure integrated melatonin values and FSH, LH, testosterone, or estradiol profiles, it seems that the antigonadal action of melatonin is not related to circulating gonadotropin, PRL, or sex steroid levels. Similar observations were also demonstrated by some investigators (6,12,13). In contrast, others found a modulatory relationship between melatonin and sex steroids (2, 14, 15).…”

supporting

confidence: 91%

Body composition derived from whole body counting of potassium in GH deficient adults.

Forbes¹

1996

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

section of our paper, we aimed to determine only alterations of day-time (early morning), but not nocturnal, plasma melatonin levels to investigate the role of melatonin in male hypogonadism and the effects of treatment on its plasma levels. Furthermore, early morning measurement of elevated melatonin could mean an increase in total melatonin production; however, they also could mean a delay in the early morning fall in melatonin secretion. We, as others (2,3), have been able to confirm the increased circulating melatonin in patients with IHH, and a tendency is also pointed to in primary hypogonadism, even using a single determination. Although subtle time-dependent changes in circadian melatonin secretion are best identified by sampling an individual subject at frequent intervals for a 24-h period, and interindividual variation in plasma melatonin levels is substantial, it has previously been shown that intraindividual variations tend to be relatively small (4-7). Moreover, Luboshitzky et al. (7) recently suggested that melatonin secretory patterns are specific for each individual. We have, therefore, evaluated melatonin levels in blood samples drawn at the same time (0730 h) before and after therapy to prevent the effect of intraindividual variation on melatonin levels.Short-term treatment with gonadotropins or testosterone, although inducing significant increases in circulating testosterone, did not achieve normal testosterone levels, either in primary or in secondary hypogonadal patients. Therefore, decreases in melatonin observed in both groups may not have reached significant differences, because of an insufficient testosterone milieu. Also, as demonstrated recently by Luboshitzky et al. (7) (after 4 months of testosterone treatment), it can not be ruled out that a much more prolonged time of treatment may be necessary to obtain significant changes in plasma melatonin.The recent demonstrations of melatonin receptors on human granulosa cell membranes (8) and prostate glandular epithelium (9), 'ZSI-labeled binding sites in the testes and ovaries of the duck (lo), and androgen receptors in rat pinealocytes (11) suggest a direct relation between the pineal and the gonad. In our study, observation of a tendency for melatonin to decrease after treatment in both groups suggests some degree of regulation of melatonin secretion by gonadal steroids or gonadotropins. However, we failed to demonstrate any correlation between early morning melatonin and circulating gonadotropin, PRL, and gonadal steroid levels. Although we did not measure integrated melatonin values and FSH, LH, testosterone, or estradiol profiles, it seems that the antigonadal action of melatonin is not related to circulating gonadotropin, PRL, or sex steroid levels. Similar observations were also demonstrated by some investigators (6, 12, 13). In contrast, others found a modulatory relationship between melatonin and sex steroids (2, 14, 15). Thus, the regulation of melatonin by sex steroids requires further investigation. Furthermore, the lack of an ...

show abstract

Nocturnal melatonin levels are unaltered by ovarian suppression in girls with central precocious puberty

Cited by 27 publications

References 23 publications

Effects of testosterone treatment on plasma melatonin levels in male hypogonadism

Effects of testosterone treatment on plasma melatonin levels in male hypogonadism

The amplitude of nocturnal melatonin concentrations is not decreased by oestradiol and does not alter reproductive function in adolescent or adult female rhesus monkeys

Body composition derived from whole body counting of potassium in GH deficient adults.

Contact Info

Product

Resources

About